Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martina Bebin

Showing results (61-70 of 116) with videos related to

Pageof 12
Sort By:
Epilepsy & Behavior : E&B|December 23, 2019
Language predictors of autism spectrum disorder in young children with tuberous sclerosis complexAlexandra Schoenberger, Jamie K Capal, Annie Ondracek, et al.
Epilepsy Research|April 26, 2019
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program resultsLinda C Laux, E Martina Bebin, Daniel Checketts, et al.
Journal of Neurodevelopmental Disorders|December 17, 2019
Early white matter development is abnormal in tuberous sclerosis complex patients who develop autism spectrum disorderAnna K Prohl, Benoit Scherrer, Xavier Tomas-Fernandez, et al.
Brain : a Journal of Neurology|September 24, 2020
Variant-specific changes in persistent or resurgent sodium current in SCN8A-related epilepsy patient-derived neuronsAndrew M Tidball, Luis F Lopez-Santiago, Yukun Yuan, et al.
Plos Genetics|September 1, 2017
MYT1L mutations cause intellectual disability and variable obesity by dysregulating gene expression and development of the neuroendocrine hypothalamusPatricia Blanchet, Martina Bebin, Shaam Bruet, et al.
Epilepsia|May 27, 2023
Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access ProgramRobert J Flamini, Anne M Comi, E Martina Bebin, et al.
Plos One|June 29, 2016
Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 StudyDavid N Franz, Elena Belousova, Steven Sparagana, et al.
Epilepsy & Behavior : E&B|July 15, 2018
Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromesOrrin Devinsky, Chloe Verducci, Elizabeth A Thiele, et al.
The Lancet. Oncology|December 3, 2014
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 studyDavid Neal Franz, Elena Belousova, Steven Sparagana, et al.
Human Mutation|August 21, 2012
Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complexMarianne Hoogeveen-Westerveld, Rosemary Ekong, Sue Povey, et al.
Pageof 12

Showing results (61-70 of 116) with videos related to

Sort By:
Pageof 12
Epilepsy & Behavior : E&B|December 23, 2019
Language predictors of autism spectrum disorder in young children with tuberous sclerosis complexAlexandra Schoenberger, Jamie K Capal, Annie Ondracek, et al.
Epilepsy Research|April 26, 2019
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program resultsLinda C Laux, E Martina Bebin, Daniel Checketts, et al.
Journal of Neurodevelopmental Disorders|December 17, 2019
Early white matter development is abnormal in tuberous sclerosis complex patients who develop autism spectrum disorderAnna K Prohl, Benoit Scherrer, Xavier Tomas-Fernandez, et al.
Brain : a Journal of Neurology|September 24, 2020
Variant-specific changes in persistent or resurgent sodium current in SCN8A-related epilepsy patient-derived neuronsAndrew M Tidball, Luis F Lopez-Santiago, Yukun Yuan, et al.
Plos Genetics|September 1, 2017
MYT1L mutations cause intellectual disability and variable obesity by dysregulating gene expression and development of the neuroendocrine hypothalamusPatricia Blanchet, Martina Bebin, Shaam Bruet, et al.
Epilepsia|May 27, 2023
Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access ProgramRobert J Flamini, Anne M Comi, E Martina Bebin, et al.
Plos One|June 29, 2016
Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 StudyDavid N Franz, Elena Belousova, Steven Sparagana, et al.
Epilepsy & Behavior : E&B|July 15, 2018
Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromesOrrin Devinsky, Chloe Verducci, Elizabeth A Thiele, et al.
The Lancet. Oncology|December 3, 2014
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 studyDavid Neal Franz, Elena Belousova, Steven Sparagana, et al.
Human Mutation|August 21, 2012
Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complexMarianne Hoogeveen-Westerveld, Rosemary Ekong, Sue Povey, et al.
Pageof 12